Who is sponsoring NCT03064295?

NCT03064295 is sponsored by Cedars-Sinai Medical Center.

What drugs are being tested in NCT03064295?

Interventions in NCT03064295: Myocardial Perfusion Cardiac MRI., Contrast, Pharmacologic Stress Agent.

What condition does NCT03064295 study?

NCT03064295 studies Coronary Artery Disease, Coronary Microvascular Disease.

Is NCT03064295 still recruiting?

NCT03064295 is currently status unknown. Last updated 8 February 2023.

Last reviewed 2023-02-08 · How we verify

NCT03064295

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Whole-Heart Myocardial Blood Flow Quantification Using MRI

Status unknown Last updated 8 February 2023

What this trial tests

trial testing Myocardial Perfusion Cardiac MRI. in Coronary Artery Disease in 160 participants. Status unknown.

Timeline

1 March 2018

Primary endpoint
1 January 2025

1 January 2025

Quick facts

Lead sponsor	Cedars-Sinai Medical Center
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	160
Start date	1 March 2018
Primary completion	1 January 2025
Estimated completion	1 January 2025
Sites	1 location across United States

Drugs / interventions tested

Myocardial Perfusion Cardiac MRI.
Contrast — full drug profile →
Pharmacologic Stress Agent — full drug profile →

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →
Coronary Microvascular Disease — all drugs for Coronary Microvascular Disease →

Sponsor

Cedars-Sinai Medical Center

Who can join

18 and older, any sex, with Coronary Artery Disease or Coronary Microvascular Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study hopes to provide significant technical improvement in a Myocardial Blood Flow (MBF) cardiac magnetic resonance (CMR) quantification technique to address challenges and technical limitations for MBF CMR. By developing and validating novel techniques to improve first-pass perfusion (FPP) cardiac MR, we propose to increase diagnostic accuracy by minimizing false positives and false negatives, allow for better evaluation and accurate quantification of total ischemic burden and reduce image and motion-induced artifacts. The broad, long-term objective of the proposed project is to improve the prognosis of patients with myocardial ischemia caused by coronary artery disease (CAD) or coronary microvascular dysfunction (CMD).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other Cedars-Sinai Medical Center trials

Trials by the same sponsor.

NCT06012487 — Correlates and Control of Blood Pressure Variability · Phase 1 · not yet recruiting
NCT07495995 — SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis · Phase 2 · not yet recruiting
NCT07413965 — TAVR vs SAVR in Severe Bicuspid Aortic Stenosis · NA · not yet recruiting
NCT06521021 — CHOICE to AVOID or RESIST · NA · not yet recruiting
NCT07499089 — Together-Breast Cancer Support Platform · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03064295 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cedars-Sinai Medical Center
Last refreshed: 8 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03064295.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing